Vitae Pharmaceuticals is a clinical-stage biopharmaceutical company building a portfolio of novel, small molecule, best-in-class compounds that address large markets with significant unmet medical needs, including chronic kidney disease, diabetes, atherosclerosis and Alzheimer's disease.

Patents 659show all

  • 192
    C07D - Heterocyclic compounds
  • 29
    C07C - Acyclic or carbocyclic compounds
  • 23
    A61K - Preparations for medical, dental, or toilet purposes
  • 20
    C07F - Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
  • 9
    C07B - General methods of organic chemistry
  • 8
    A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
  • 5
    Y02P - Climate change mitigation technologies in the production or processing of goods
  • 3
    Y02A - Technologies for adaptation to climate change
  • 1
    C07K - Peptides

Clinical Trials 5show all

2Phase 12Phase 1/Phase 21Phase 2

SEC Filings show all


36
8-K

6
10-Q

2
10-K

2
D

1
S-1

Contact Information

502 West Office Center Drive
Fort Washington, PA 19034
United States

Overview

Total FundingEmployeesLast Funding DateStatus
$94,000,00051-1002009-06-09Acquired

Crunchbase Investment Rounds

DateAmountRoundValuationLead InvestorOther Investors
2007-11-06$15,000,000Series DAtlas Venture, New Enterprise Associates, Venrock, Prospect Venture Partners
2009-06-09$15,000,000Series Unknown
2005-01-04$34,000,000Series BVenrock
2005-07-14$15,000,000Series CNew Enterprise Associates, Atlas Venture, Venrock, Wellcome Trust, Prospect Venture Partners
2004-01-14$15,000,000Series BNew Enterprise Associates, Prospect Venture Partners, VenrockIntel Capital

SEC Form D Funding Events

DateOfferedSoldType
2009-06-10$15,000,000$15,000,000Equity
2008-09-11Unknown Unknown Other (Paper Filing)

Key Executives

  • Jeffrey Hatfield
    Executive Officer, Director
  • Tina Fiumenero
    Executive Officer
  • Peter Barrett
    Director
  • Robert Gunderson
    Director
  • Donald Hayden
    Director
  • Charles Newhall
    Director
  • Bryan Roberts
    Director
  • James Tananbaum
    Director
  • Richard Gregg
    Executive Officer